Circassia has entered into a license agreement with NanoPass Technologies for microneedle intradermal delivery device - MicronJet.
The agreement allows Circassia to use the device with many of its products including its cat and ragweed allergy therapies.
MicronJet is a microneedle-based device used to deliver vaccines and drugs directly into the skin.
The device will also induce superior immunogenicity while maintaining a lower dose than conventional doses delivered into the muscle.
Circassia vice-chairman Charles Swingland said they intend to use the device for many of their allergy programs and have received positive feedback from patients and clinicians.